Form 4: Camp4 CSO Acquires 145,500 Stock Options

Camp4 Therapeutics' Chief Scientific Officer, Daniel Tardiff, acquired 145,500 stock options with an exercise price of $6.01, vesting over three years.

Summary

• Daniel Tardiff, Chief Scientific Officer of Camp4 Therapeutics Corp, acquired 145,500 derivative securities in the form of stock options.
• The transaction date for this acquisition was December 11, 2025.
• Each stock option has an exercise price of $6.01.
• The options have a vesting start date of December 1, 2025.
• One-third (33.33%) of the shares subject to the option will vest on the first anniversary of the vesting start date (December 1, 2026).
• The remaining shares will vest in equal monthly installments over 24 months thereafter, contingent on continued service.
• The expiration date for these stock options is December 10, 2035.
• Following this transaction, Daniel Tardiff beneficially owns 145,500 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Form 4 is a routine disclosure, the grant of stock options to a key executive like the Chief Scientific Officer indicates continued commitment to the company and aligns management's interests with long-term shareholder value. It's a standard compensation event, not indicative of immediate operational or financial changes, hence not highly positive but certainly not negative.

Positives

• The grant of stock options to the Chief Scientific Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The options represent a significant equity stake, potentially motivating the CSO to contribute to the company's growth and value creation.

Future Outlook

This filing is a disclosure of an insider transaction and does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The grant of stock options is a common form of equity compensation for executives in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key talent by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to a Chief Scientific Officer is a standard practice in the biotech industry for executive compensation, comparable to similar grants at companies like Moderna, BioNTech, or Regeneron, which frequently use equity to incentivize R&D leadership.
• The vesting schedule, with a one-year cliff followed by monthly installments over two years, is also a common structure designed to encourage long-term commitment and performance, aligning with typical industry benchmarks for executive retention.

Stakeholder Impact

• Shareholders: The grant of options aims to align the Chief Scientific Officer's incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: This compensation structure may serve as a benchmark or motivator for other key employees, reinforcing the company's approach to talent retention and incentive programs.

Next Steps

• The stock options will begin to vest according to the specified schedule, with the first one-third vesting on December 1, 2026, subject to Daniel Tardiff's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the grant of stock options to a key executive. While it signals continued alignment of management's interests with shareholders, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard compensation event, and therefore, a 'hold' recommendation is appropriate as it doesn't present a compelling reason to buy or sell based solely on this disclosure.

Keywords

Camp4 Therapeutics, CAMP, Daniel Tardiff, Chief Scientific Officer, Stock Option, Insider Transaction, SEC Form 4, Equity Compensation